CBD Clinical Trial
Official title:
Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task
Cannabidiol (CBD) is another cannabis plant derivative for which, like THC, there has been extensive research. Unlike THC however, CBD is non-intoxicating and non-psychedelic. CBD has antipsychotic effects. Logically, if CBD opposes THC effects, it may be a potential antipsychotic treatment. The purpose of this pilot research is to show target engagement of the hippocampus with the study drug (CBD versus placebo) in patients who have been diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder with psychosis compared to healthy controls.
The investigators conjecture that CBD may act both to modify THC effects and to reduce psychosis symptoms (at least in part) through downstream ECS-related mechanisms, both of which actions converge on the hippocampus, a region rich in CB1 receptors. As such, observing hippocampus activity levels using fMRI can be an effective means of measuring CBD target engagement within this pilot study context. The purpose of this pilot research is to show target engagement of the hippocampus with the study drug cannabidiol (CBD) versus placebo, in BSNIP Biotype 3 compared to Biotypes 1 and 2 and to healthy control subjects, during performance of an fMRI paired associated memory task. Here, investigators will use B-SNIP-based observations in already-characterized B-SNIP subjects, to predict in which individuals CBD engages a theoretically-based brain target. In turn (in future planned studies) such engagement may predict CBD treatment responders. At present, CBD is still an experimental drug for psychosis treatment (although now FDA-approved for treatment of specific types of childhood seizures), but one with a rather benign side-effect profile that could easily be added to ongoing antipsychotic treatment. The purpose of the study is to study response to a single, acute dose of CBD compared to placebo, under double-blind conditions in a small-scale pilot study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04976738 -
A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04729244 -
The Study of Hemp Oil CBD for Evaluation of Efficacy and Safety in Treatment of Pain, Anxiety and Insomnia Management
|
Phase 1 | |
Recruiting |
NCT05490511 -
Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus
|
Phase 1 | |
Withdrawn |
NCT04412837 -
The Use of Cannabinoid Patch for Knee Osteoarthritis
|
Phase 2 | |
Completed |
NCT05121506 -
A Study to Investigate the Bioavailability and Skin Absorption of CBD and THC From GT4 Technology in Healthy Adults
|
Phase 1 | |
Completed |
NCT04360044 -
Efficacy of Inhaled Cannabis for Acute Migraine Treatment
|
Phase 2 | |
Recruiting |
NCT04611347 -
Topical CBD in Joint Arthritis
|
Phase 2 | |
Enrolling by invitation |
NCT04680130 -
Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders
|
||
Recruiting |
NCT04398719 -
CBD-Microglia PET Study
|
Early Phase 1 | |
Completed |
NCT04423341 -
Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04997954 -
EMERALD TRIAL Open Label Extension Study
|
Phase 4 | |
Recruiting |
NCT04030442 -
Cannabidiol, Morphine, Pain
|
Phase 1 | |
Completed |
NCT04851392 -
Do Adolescents and Adults Differ in Their Acute Response to Cannabis?
|
N/A | |
Completed |
NCT04777643 -
Sex Differences in Neural Response to Cannabidiol
|
Early Phase 1 | |
Recruiting |
NCT05956834 -
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
|
||
Recruiting |
NCT05562635 -
CBD (Cannabidiol) Intraoral Application and TMD (Temporomandibular Disorders)
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04831294 -
Effects of Cannabidiol (CBD) on the Brain
|
N/A | |
Recruiting |
NCT04686539 -
Synthetic CBD as a Therapy for COVID-19
|
Phase 1 | |
Active, not recruiting |
NCT04482244 -
RCT of CBD for Anxiety in Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT04775030 -
Methodology for Developing an Occlusal Appliance With CBD Active Carrier
|
Phase 2/Phase 3 |